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Abstract
Background: Objective measurement of airflow obstruction by spirometry is an essential part of the diagnosis of
asthma or COPD. During exacerbations, the feasibility and utility of spirometry to confirm the diagnosis of asthma
or chronic obstructive pulmonary disease (COPD) are unclear. Addressing these gaps in knowledge may help define
the need for confirmatory testing in clinical care and quality improvement efforts. This study was designed to
determine the feasibility of spirometry and to determine its utility to confirm the diagnosis in patients hospitalized
with a physician diagnosis of asthma or COPD exacerbation.
Methods: Multi-center study of four academic healthcare institutions. Spirometry was performed in 113 adults
admitted to general medicine wards with a physician diagnosis of asthma or COPD exacerbation. Two
board-certified pulmonologists evaluated the spirometry tracings to determine the proportion of patients able to
produce adequate quality spirometry data. Findings were interpreted to evaluate the utility of spirometry to
confirm the presence of obstructive lung disease, according to the 2005 European Respiratory Society/American
Thoracic Society recommendations.
Results: There was an almost perfect agreement for acceptability (κ= 0.92) and reproducibility (κ =0.93) of
spirometry tracings. Three-quarters (73%) of the tests were interpreted by both pulmonologists as being of
adequate quality. Of these adequate quality tests, 22% did not present objective evidence of obstructive lung
disease. Obese patients (BMI ≥30 kg/m
2) were more likely to produce spirometry tracings with no evidence of
obstructive lung disease, compared to non-obese patients (33% vs. 8%, p= 0.007).
Conclusions: Adequate quality spirometry can be obtained in most hospitalized adults with a physician diagnosis
of asthma or COPD exacerbation. Confirmatory spirometry could be a useful tool to help reduce overdiagnosis of
obstructive lung disease, especially among obese patients.
Keywords: Asthma, COPD, Exacerbation, Hospitalization, Spirometry, Quality improvement
Background
Exacerbations of asthma or chronic obstructive pulmon-
ary disease (COPD), the most common obstructive lung
diseases, account for more than one million hospitaliza-
tions and nearly six million hospital days each year in the
US alone [1-4]. Readmission rates at 30 days, following
hospitalization for asthma and COPD exacerbations, are
approximately 10% and 20%, respectively [5-7]. Readmis-
sion rates at 90-days in patients with COPD exacerba-
tions are estimated to be about 35% [8]. In-hospital
mortality for patients admitted with asthma or COPD
exacerbations ranges from 0.2% to 38%; higher mortality
rates correspond to populations with a greater acuity of
illness, including those requiring mechanical ventilation
[2,7-9]. The economic burden from these hospitalizations
and re-admissions is enormous; annual direct costs are
estimated to be $16 billion, representing more than 30%
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[3].
Studies performed using International Classification of
Diseases, ninth revision, (ICD-9) billing codes or
physician-documented diagnosis to identify the study
population, indicate that up to 50% of patients hospita-
lized with asthma or COPD exacerbations do not receive
guideline recommended care [10,11]. In a previous study
using chart abstraction, we found that relying on ICD-9
billing codes may lead to overdiagnosis of COPD exacer-
bations in up to 25% of patients, potentially because
confirmatory testing (e.g. spirometry) to document ob-
structive lung disease is rarely performed [12]. To our
knowledge, similar data on asthma exacerbations is not
available. Objective measurement of expiratory airflow
obstruction is considered essential to the diagnosis of
asthma and COPD, as other diseases can present with
similar symptoms. A recently completed audit of
patients hospitalized for COPD exacerbations found sub-
stantial variations in care, with spirometry prior to hos-
pital admissions available in only about three-quarters of
patients [8]. While confirmatory spirometry is recom-
mended by the European Respiratory Society/American
Thoracic Society guidelines to establish a diagnosis of
asthma or COPD, is not routinely performed during
hospitalizations for exacerbations, due to concerns about
its feasibility (e.g., inadequate test quality) and a lack of
data supporting its utility.
There is a paucity of data about the feasibility of meas-
uring lung function in hospitalized patients suspected of
having an asthma or COPD exacerbation. A recent
single-hospital study by Rea and colleagues [13] found
that spirometry, performed upon hospital discharge, can
serve as a baseline against which post-discharge mea-
surements can be compared. However, we are not aware
of studies that have specifically examined the quality of
spirometry tests obtained early in the course of hospita-
lizations for patients with COPD or asthma exacerba-
tions and their utility in confirming the presence of
obstructive lung disease.
Rea and colleagues also showed that approximately
16% of patients hospitalized with COPD exacerbations
did not meet the GOLD criteria for COPD by spirom-
etry on hospital discharge [13]. Data about the preva-
lence of patients with a physician diagnosis of an asthma
exacerbation but in whom spirometry fails to confirm
obstructive lung disease (i.e., overdiagnosis) are lacking.
To address these gaps in knowledge, we conducted a
multi-center study in adults hospitalized with a phys-
ician diagnosis of asthma or COPD exacerbation to: a)
evaluate the quality of spirometry tracings; and b) assess
the utility of confirmatory spirometry for the presence of
obstructive lung disease in patients hospitalized with a
physician diagnosis of asthma or COPD exacerbation.
The findings reported in this study may help determine
the need for confirmatory testing in clinical care setting,
or as part of quality improvement efforts, such as pay-
for-performance, in adults hospitalized with a physician
diagnosis of asthma or COPD exacerbation.
Methods
Patient population
As part of several hospital-based studies [14,15], we
screened admission logs to identify adults admitted for
asthma or COPD exacerbations at four university-
affiliated medical centers (The Johns Hopkins Hospital,
Johns Hopkins Bayview Medical Center, The University
of Chicago Medical Center, and Mercy Hospital and
Medical Center). The general medicine treating phys-
ician of each potential participant was contacted for ver-
bal assent to approach their patient, using standardized
text, and to confirm the diagnosis of asthma or COPD
exacerbation. Since the participants received standard
care while in the hospital, a physician diagnosis of
asthma or COPD exacerbation was sufficient. Written
informed consent was obtained from patients who met
all inclusion criteria (age ≥18 years, admitted to the
general ward, and physician diagnosis of asthma or
COPD exacerbation). Patients with additional respiratory
diagnosis (e.g., sarcoidosis), too ill to provide informed
consent according to the treating physician, or admitted
to the intensive care unit at the time of screening were
excluded. Demographic information (date of birth, gen-
der, self-reported height, self-reported weight) was col-
lected from patients at the time spirometry was
performed. Medical records were reviewed to collect data
on the date of hospital admission and discharge. The
study was approved by the Institutional Review Board at
each medical center (University of Chicago Medical Cen-
ter protocol numbers 15729A, 14831A, John Hopkins
Hospital and John Hopkins Bayview Medical Center
protocol numbers 03-08-19-02, 03-08-10-02, no protocol
number provided by Mercy Hospital and Medical
Center).
Study procedures
As part of the study procedures, admission logs were
scanned daily to identify potential study participants.
Spirometry is rarely performed on hospital admission as
part of routine clinical care. Thus, for this study, spirom-
etry was performed as early as possible during
hospitalization without interfering with patient care (e.g.,
treatments, other tests, evaluations being performed by
the clinical team). Study staff administered 2 puff of
inhaled albuterol and conducted post-bronchodilator
spirometry tests at the bedside. Spirometry tests were
performed using a Koko spirometer (KoKo
W; Pulmonary
Data Services Instrumentation; Louisville, CO) while
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with flow volume loops were obtained using European
Respiratory Society/American Thoracic Society (ERS/
ATS) recommendations; each participant completed up
to eight efforts to measure the FEV1 and FVC [16].
Assessment of quality of spirometry tracings
Two board-certified pulmonologists independently rated
spirometry tracings according to the ERS/ATS criteria
[17]. To be considered of adequate quality, spirometry
tracings had to satisfy the criteria for both acceptability
and reproducibility. A spirometry tracing was considered
acceptable if it showed at least three efforts meeting
criteria for an acceptable beginning of test (back-
extrapolated volume [BEV] <150ml or <5% of forced vital
capacity [FVC], whichever is greater), middle of test (no
artifacts [e.g., glottis closure, cough or hesitation]), and
end of test (exhalation of at least 6 seconds or a plateau
before 6 seconds). A test was considered reproducible if
the difference between the two highest forced expired
volumes in the first second (FEV1) and FVC values were
both <150ml (or <100ml if FVC <1L). A spirometry test
had to fulfill the criteria for acceptability and reproduci-
bility by both raters to be considered adequate quality.
Assessment of utility of confirmatory spirometry
The utility of confirmatory spirometry was determined
by assessing the percentage and demographic character-
istics of patients without evidence of airflow obstruction
by spirometry. Obstructive lung disease was defined as
FEV1/FVC <lower limit of normal (LLN); the LLNs were
calculated using NHANES III-predicted equations [18].
Statistical analysis
Descriptive statistics employed proportions. Medians
and interquartile range (IQR) were used to describe the
days from hospital admission to spirometry testing. We
calculated the kappa (κ) statistic to evaluate agreement
between raters regarding acceptability and reproducibil-
ity of spirometry tracings [19]. Body-mass index (BMI)
was calculated and categorized according to the WHO
criteria [20]. Bivariate analyses employed a χ
2, Fisher’s
exact, or Wilcoxon rank-sum tests, where appropriate.
All reported p-values are two sided, and p-values of
<0.05 were considered statistically significant. Analyses
were performed using STATA software package, release
10.0 (Stata Corp Inc, College Station, Texas).
Results
Patient characteristics
Of the 113 participants in the study, 68% were female,
63% were between the ages of 35 and 64, 56% were
obese and 59% were admitted with a diagnosis of asthma
exacerbation. Participants with a diagnosis of asthma ex-
acerbation were younger and had higher BMIs (e.g., 61%
vs. 48% had BMI ≥30 kg/m
2) than those with a diagnosis
of COPD exacerbation (Table 1). The median (IQR)
time from admission to spirometry testing was 1 day
(1 to 2 days).
Spirometry quality
Overall, nearly three-quarters of spirometry tests (73%)
were graded as being of adequate quality, with a similar
proportion in patients with a diagnosis of asthma and
COPD exacerbation (Table 2). There were discordant
interpretations by the two raters regarding the acceptability









<35 20 (18%) 18 (27%) 2 (4%) <0.0001
35-64 71 (63%) 44 (66%) 27 (59%)
≥65 22 (19%) 5 (7%) 17 (37%)
Female 77 (68%) 48 (72%) 29 (63%) 0.41
BMI, kg/m
2
<18.5 (Underweight) 7 (6%) 0 (0%) 7 (15%) 0.009
18.5-24.9 (Normal) 22 (19%) 11 (16%) 11 (24%)
25-29.9 (Overweight) 21 (19%) 15 (22%) 6 (13%)
≥30 (Obese) 63 (56%) 41 (61%) 22 (48%)
Median days from hospital admission
spirometry testing (IQR)
1 (1 to 2) 1 (1 to 2) 1 (1 to 2) 0.77
Values above represent n (column %), unless otherwise specified.
Abbreviations: IQR, interquartile range.
* Due to rounding, percentages may not add to 100%.
Prieto Centurion et al. BMC Pulmonary Medicine 2012, 12:73 Page 3 of 7
http://www.biomedcentral.com/1471-2466/12/73of only 3 (2%) spirometry tracings; there were no discord-
ant interpretations regarding reproducibility among tra-
cings graded as being acceptable by both raters. There was
almost perfect agreement for acceptability (κ=0 .9 2) an d
reproducibility (κ =0.93).
Among tracings interpreted as not being acceptable by
at least one rater (n=25/113 for rater 1; n =22/113 for
rater 2), the most common reason was failure to meet end
of test criteria (20/25 for rater 1; 17/22 for rater 2). Tests
also failed to meet start of test criteria (11/25 for rater 1;
11/22 for rater 2) or middle of test criteria (14/25 for rater
1; 11/22 for rater 2). Reasons for which tests failed to meet
acceptability criteria did not vary depending on age, gender,
physician diagnosis or BMI (Additional file 1: Table S1).
There was a trend suggesting that tracings rated as not
adequate quality were associated with a shorter interval
between hospital admission and performance of spirom-
etry (median [IQR] days 1 [0–1] for not adequate quality
tests vs. 1 [0–2] for adequate quality, p=0.06). None of
the other patient characteristics we examined were asso-
ciated with adequate vs. not adequate spirometry tracings
(p-values >0.2).
Spirometry interpretation and assessment of utility
Among the 83 tests that were considered to be adequate
quality by both raters, obstructive lung disease was
confirmed in only four of five tests (78%) (Table 3). In
those with confirmed obstructive lung disease, the mean
(SD) % predicted FEV1 and FEV1/FVC were 43% (16%)
and 56% (10%), respectively. In those with a diagnosis of
asthma exacerbation, obstructive lung disease was con-
firmed in 83% versus 72% with a diagnosis of COPD
exacerbation (p= 0.29). Thus, approximately 1 in 5
patients did not have spirometric evidence of obstructive
lung disease. Participants without evidence of obstructive
lung disease were significantly more likely to have higher
BMIs (p=0.009). Obese participants (i.e., BMI ≥30 kg/m
2)
were four times more likely than non-obese participants
to be misclassified as having airflow obstruction (33 vs.
8%, p=0.007). None of the other patient characteristics
we examined were associated with a lack of evidence of
obstructive lung disease. The number of days between
hospital admission and spirometry testing was also not
associated with a lack of obstructive lung disease.
Spirometry and flow volume loop configurations
suggested alternate abnormalities, including variable
extrathoracic airflow obstruction and restrictive lung
disease among tests that did not meet criteria for ob-
structive lung disease.
Discussion
In this study, we demonstrated that adequate quality
spirometry can be obtained in three-quarters of












Asthma exacerbation 47 (78%) 20 (22%) 0.23
COPD exacerbation 36 (70%) 10 (30%)
Age, years
<35 14 (70%) 6 (30%) 0.91
35-64 53 (75%) 18 (25%)
≥65 16 (73%) 6 (27%)
Female 57 (73%) 21 (27%) 0.50
BMI, kg/m
2
<18.5 (Underweight) 5 (71%) 2 (29%) 0.82
18.5-24.9 (Normal) 16 (73%) 6 (27%)
25-29.9 (Overweight) 17 (81%) 4 (19%)
≥30 (Obese) 45 (71%) 18 (29%)
Median days from hospital
admission to spirometry
testing (IQR)
1 (1 to 2) 1 (0 to 2) 0.06
Values above represent n (row %), unless otherwise specified.
Abbreviations: IQR Interquartile range.
* Due to rounding, percentages may not add to 100%.
† Includes spirometry tracings in which one (n = 25, 22%) or both (n = 22,
19%) raters graded the effort as not acceptable or not reproducible based on
ERS/ATS criteria.
Table 3 Characteristics of patients with adequate quality







n=65 (78%) n=18 (22%)
Clinical diagnosis
Asthma exacerbation 39 (83%) 8 (17%) 0.29
COPD exacerbation 26 (72%) 10 (28%)
Age, years
<35 11 (79%) 3 (21%) 0.55
35-64 43 (81%) 10 (19%)
≥65 11 (69%) 5 (31%)
Female 42 (72%) 14 (25%) 0.40
BMI, kg/m
2
<18.5 (Underweight) 4 (80%) 1 (20%) 0.009
18.5-24.9 (Normal) 16 (100%) 0 (0%)
25-29.9 (Overweight) 15 (88%) 2 (12%)




1 (1 to 2) 1 (1 to 2) 0.30
Values represent n (row %), unless otherwise noted. Abbreviations: IQR
Interquartile range.
* Only in patients for which both raters reported acceptable and reproducible
tracings.
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asthma or COPD exacerbation. Spirometry confirmed
obstructive lung disease in 78% of participants with ad-
equate quality tests; in other words, about 1 in 5 partici-
pants with a physician diagnosis of asthma or COPD
exacerbation did not meet the diagnostic criteria by spir-
ometry. Overdiagnosis was about four times more likely
in obese than in non-obese patients.
Our finding demonstrates that adequate quality spir-
ometry can be obtained early in the hospital course in
most patients with asthma or COPD exacerbations. This
finding expands previous work by Rea and colleagues
[13], who showed that patients hospitalized with COPD
exacerbations were able to perform spirometry on the
day of discharge. None of the participant characteristics
we examined were different between those who were able
to produce adequate vs. not adequate quality spirometry,
except for a trend between the number of days between
hospital admission and spirometry testing. We found a
trend suggesting that a shorter number of days between
hospital admission and spirometry testing may be asso-
ciated with the inability to produce adequate spirom-
etry. We suspect that the length of hospital stay
before spirometry testing is linked to the acuity of ill-
ness (i.e. sicker patients were unable to perform spir-
ometry). Therefore, an important limitation to our
study is that patients who were too ill to provide
informed consent and those who were admitted to
the intensive care unit were excluded; such patients
may be even more likely to not perform adequate
quality spirometry tests.
Recent studies of spirometry in the primary care setting
have shown that up to 50% of patients with a physician
diagnosis of COPD did not meet the criteria for the diag-
nosis by spirometry [21-23]. Similarly, a recent study
showed that more than 30% of patients with a physician
diagnosis of stable asthma did not meet the criteria for the
diagnosis when tested with a combination of spirometry
and methacholine challenge test [24]. To our knowledge,
the present report is the first study to evaluate the fre-
quency of misclassification among hospitalized patients
with a physician diagnosis of asthma exacerbation.
Additionally, we found that the lack of evidence for
obstructive lung disease was four times more common
in obese vs. non-obese participants. Our findings in hos-
pitalized patients are consistent with results observed in
a study of outpatients in a primary care setting that
identified higher rates of misclassification for COPD in
overweight or obese patients [22]. Similarly, previous
studies have suggested that overweight or obese patients
may be over-diagnosed as having asthma. For example,
one study reported that nearly 1 in 3 overweight or
obese subjects diagnosed with asthma do not actually
have airway hyperresponsiveness [25]. Other studies,
including some in obese patients, found that medical
history and physical examination findings may not be
sufficiently reliable to diagnose obstructive lung disease
[26,27]. Other data suggest that vocal cord dysfunction
may mimic an asthma exacerbation [28], which may help
explain why some spirometry tracings had evidence of
variable extrathoracic airflow obstruction. In our study,
we found that some patients hospitalized with a diagno-
sis of asthma or COPD exacerbation presented spirom-
etry tracings suggestive of restrictive (not obstructive)
lung disease. Thus, together with previously published
evidence, our findings suggest that a range of conditions
may be contributing to respiratory symptoms diagnosed
as asthma or COPD exacerbations.
This multicenter study had multiple strengths. First,
spirometry was performed on average within 1 day of
hospitalization, decreasing the likelihood that partici-
pants were tested after the resolution of the exacerba-
tion. Second, we prospectively identified patients with a
physician diagnosis of asthma or COPD exacerbation
and in whom the treating physician did not suspect
other respiratory conditions, rather than relying on chart
abstraction or billing codes. Lastly, we employed stan-
dardized spirometry procedures using ERS/ATS guide-
lines, minimizing any variations in the procedure or
interpretation.
There were also several potential limitations to our
study. We relied on spirometry to diagnose obstructive
lung disease and may have missed mild air trapping or
increased peripheral airway resistance that would require
the use of special diagnostic tests, such as body plethys-
mography or impulse oscillometry. However, ERS/ATS
guidelines for the diagnosis of asthma or COPD are
based on spirometry and do not require the use of such
tests. Also, as participants were enrolled with respiratory
symptoms requiring hospitalization, the likelihood of
milder forms of airway disease requiring more sensitive
tests would be very low. We relied on self-reported
height and weight to determine the predicted spirometry
results, which may not be as reliable as objective meas-
urement of height and weight. We also enrolled a mod-
est number of participants (n = 113) in four academic
medical centers and we do not know if these results
would be generalizable to other healthcare institutions
(e.g., community hospitals). However, our results high-
light the need for larger, multi-center studies to further
evaluate the overdiagnosis of asthma and COPD exacer-
bations in hospitalized patients. Last, we only had lim-
ited data about patient characteristics. Additional
information on the exacerbation severity and cognitive
ability of the participants could have helped identify
other characteristics associated with the inability to ob-
tain adequate quality tests. We did not collect data
regarding the comorbid conditions in patients without
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heart failure); this information may have offered clues
into alternative diagnoses. Further, it is possible that the
high proportion of obese patients without evidence of
obstructive lung disease is due to residual confounding
factors, such as respiratory muscle weakness, that were
not measured in our study. Findings in this report can
help to inform the design of larger multi-center, longitu-
dinal studies that include community hospitals to assess
differences in accuracy across institutions and within
subgroups of patients.
Conclusion
The study findings have several implications. First, the
relatively high frequency of adequate quality spirometry
tests (about three-quarters of patients tested) should be
encouraging to clinicians who may want to use spirom-
etry in the inpatient setting to confirm the diagnosis of
asthma or COPD exacerbations. Second, the high rates
of patients who did not meet the asthma or COPD diag-
nostic criteria by spirometry (about 20%), which were
even higher among obese patients (33%). Given these
findings, we recommend that clinicians routinely obtain
spirometry in hospitalized patients suspected of having
an asthma or a COPD exacerbation.
In conclusion, we found that adequate quality spirom-
etry can be obtained in most patients hospitalized with
exacerbations of asthma or COPD. Clinical practice and
quality improvement efforts that include spirometry for
confirmation of obstructive lung disease may help to re-
duce the risk of overdiagnosis, which could lead to in-
appropriate care in this population.
Additional file
Additional file 1: Table S1. Characteristics of patients with acceptable
and not acceptable spirometry.
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